<div id="readability-page-1">Reviva Pharmaceuticals (NASDAQ:RVPH) announced on Thursday a public offering with existing and new healthcare-focused institutional investors for the purchase and sale of 27M shares of its common stock together with Series E warrants and Series F warrants, at a combined offering price of $0.335 per share, for gross proceeds of approximately $9M.   ...</div>

RVPH

<p>Reviva Pharmaceuticals（納斯達克代碼：RVPH）宣佈公開發行 2700 萬股普通股，以及 E 系列和 F 系列認股權證，定價為每股 0.335 美元，預計總收益約為 900 萬美元。該公司計劃將淨收益用於研發、營運資金及其他一般企業用途</p>

Reviva Pharmaceuticals 宣佈 900 萬美元公開發行的定價